These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 20546320)

  • 1. Long-term, open-label safety study of oral almotriptan 12.5 mg for the acute treatment of migraine in adolescents.
    Berenson F; Vasconcellos E; Pakalnis A; Mao L; Biondi DM; Armstrong RB
    Headache; 2010 May; 50(5):795-807. PubMed ID: 20546320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Almotriptan for the acute treatment of adolescent migraine.
    Lewis DW
    Expert Opin Pharmacother; 2010 Oct; 11(14):2431-6. PubMed ID: 20828268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zolmitriptan oral tablet in migraine treatment: high placebo responses in adolescents.
    Rothner AD; Wasiewski W; Winner P; Lewis D; Stankowski J
    Headache; 2006 Jan; 46(1):101-9. PubMed ID: 16412157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral almotriptan: practical uses in the acute treatment of migraine.
    Dowson AJ
    Expert Rev Neurother; 2004 May; 4(3):339-48. PubMed ID: 15853532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of almotriptan in early intervention for treatment of acute migraine in a primary care setting: the START study.
    Lanteri-Minet M; Díaz-Insa S; Leone M; Vila C; Clissold SP;
    Int J Clin Pract; 2010 Jun; 64(7):936-43. PubMed ID: 20584227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Almotriptan in the acute treatment of migraine in patients 11-17 years old: an open-label pilot study of efficacy and safety.
    Charles JA
    J Headache Pain; 2006 Apr; 7(2):95-7. PubMed ID: 16688412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A long-term open-label study of oral almotriptan 12.5 mg for the treatment of acute migraine.
    Mathew NT;
    Headache; 2002 Jan; 42(1):32-40. PubMed ID: 12005273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of trigger factors on the efficacy of almotriptan as early intervention for the treatment of acute migraine in a primary care setting: the START study.
    Leone M; Vila C; McGown C
    Expert Rev Neurother; 2010 Sep; 10(9):1399-408. PubMed ID: 20819011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of efficacy, tolerability, and treatment satisfaction with almotriptan in 3 consecutive migraine attacks. The migraine--satisfaction with treatment: reality with Almogran study.
    Massiou H; Pradalier A; Donnet A; Lanteri-Minet M; Allaf B
    Eur Neurol; 2006; 55(4):198-203. PubMed ID: 16772716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and tolerability of short-term preventive frovatriptan: a combined analysis.
    MacGregor EA; Brandes JL; Silberstein S; Jeka S; Czapinski P; Shaw B; Pawsey S
    Headache; 2009 Oct; 49(9):1298-314. PubMed ID: 19788471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case Report: Rizatriptan-Induced Ischemic Colitis.
    Fonseka GR; Kurchin A
    Headache; 2015; 55(7):1008-9. PubMed ID: 25881718
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment response and tolerability of frovatriptan in patients reporting short- or long-duration migraines at baseline.
    Kelman L; Harper SQ; Hu X; Campbell JC
    Curr Med Res Opin; 2010 Sep; 26(9):2097-104. PubMed ID: 20642390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eletriptan: a review of its use in the acute treatment of migraine.
    McCormack PL; Keating GM
    Drugs; 2006; 66(8):1129-49. PubMed ID: 16789799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Focus on trial endpoints of clinical relevance and the use of almotriptan for the acute treatment of migraine.
    Sandrini G; Dahlöf CG; Mathew N; Nappi G
    Int J Clin Pract; 2005 Nov; 59(11):1356-65. PubMed ID: 16236092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Almotriptan efficacy in migraine with allodynia: a rebuttal to Burstein and Jakubowski's critique of Schoenen et al.
    Schoenen J; Vandenheede M
    Cephalalgia; 2010 Sep; 30(9):1147-8. PubMed ID: 20713568
    [No Abstract]   [Full Text] [Related]  

  • 16. Rapid responders to frovatriptan in acute migraine treatment: results from a long-term, open-label study.
    Spierings EL; Keywood C
    Pain Med; 2009; 10(4):633-8. PubMed ID: 19453958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early intervention with almotriptan: results of the AEGIS trial (AXERT Early Migraine Intervention Study).
    Mathew NT; Finlayson G; Smith TR; Cady RK; Adelman J; Mao L; Wright P; Greenberg SJ;
    Headache; 2007 Feb; 47(2):189-98. PubMed ID: 17300358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of almotriptan 12.5 mg in achieving migraine-related composite endpoints: a double-blind, randomized, placebo-controlled study in patients controlled study in patients with previous poor response to sumatriptan 50 mg.
    Diener HC
    Curr Med Res Opin; 2005 Oct; 21(10):1603-10. PubMed ID: 16238900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myalgia and cramps associated with zolmitriptan.
    Alonso-Navarro H; Jiménez-Jiménez FJ
    Clin Neuropharmacol; 2005; 28(5):241-2. PubMed ID: 16239765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient satisfaction with eletriptan in the acute treatment of migraine in primary care.
    Nett RB; Tiseo PJ; Almas M; Sikes CR
    Int J Clin Pract; 2007 Oct; 61(10):1677-85. PubMed ID: 17877653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.